Initiated Maxim Group
Initiated Dawson James
Initiated The Benchmark Company
Initiated Rodman & Renshaw
Oct-09-20 08:01AM Lifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc. (NYSE: ARA), BMC Stock Holdings, Inc., Builders FirstSource, Inc., Cancer Genetics, Inc., Cellular Biomedicine Group, Inc., Eidos Therapeutics, Inc., Montage Resources Corporation, MyoKardia, Inc. and Yintech Investment Holdings Limited PR Newswire
Sep-25-20 04:55PM Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (NASDAQ: CGIX), Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), Otelco Inc. (NASDAQ: OTEL), Rosetta Stone Inc. (NYSE: RST), Varian Medical Systems, Inc. (NYSE: VAR), and Yintech Investment Holdings Limited (NASDAQ: YIN) PR Newswire
Sep-16-20 01:24PM Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc., (NASDAQ:CGIX) GlobeNewswire
Sep-10-20 08:50PM Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., BMC Stock Holdings, Inc., Builders FirstSource, Inc., Broadway Financial Corporation, Cancer Genetics, Inc., Proteostasis Therapeutics, Inc., Rosetta Stone Inc., and Yintech Investment Holdings Limited PR Newswire
Aug-26-20 06:39PM Lifshitz Law Firm, P.C. Announces Investigation of Cancer Genetics, Inc., Jernigan Capital, Inc., Momenta Pharmaceuticals, Inc., NTN Buzztime, Inc., Principia Biopharma Inc., Spring Bank Pharmaceuticals, Inc., Varian Medical Systems, Inc., and Yintech Investment Holdings Limited PR Newswire -9.08%
Jun-25-19 07:24AM American City Business Journals
Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite